News & Updates

Show Multimedia Only

Secukinumab shows sustained improvement in paediatric psoriasis

Secukinumab shows sustained improvement in paediatric psoriasis

Treatment with either low-dose (LD) or high-dose (HD) secukinumab showed continued improvement in PASI* and IGA** responses up to 24 weeks in children and adolescents with moderate-to-severe plaque psoriasis, according to updated results of a trial presented at PAS 2021.

Secukinumab shows sustained improvement in paediatric psoriasis

Severe atopic eczema ups mortality risk in adults

Severe atopic eczema ups mortality risk in adults

Very severe and predominantly active atopic eczema seems to increase mortality risk among adults, a recent study has found.

Severe atopic eczema ups mortality risk in adults

Something went wrong.